Best Life Sciences Companies in Brisbane, Australia
The 53 best Life Sciences companies in Brisbane, Australia in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: QBiotics.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Brisbane
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Alsonex Developer of therapeutics for neurodegenerative disease | — | — | Unfunded | Brandon D Lewis Co-Founder | — | — | — | — |
| 2 | ApnoScore Developer of smart devices for sleep monitoring | — | — | Deadpooled | Dylan Rowe Co-Founder & Electrical Engineer | — | — | — | — |
| 3 | Arthritis Relief Plus Developer of therapeutic solutions for treating arthritis | — | — | Funding Raised | Persis Anderson Founder & MD | — | — | 13 patents Patents concentrated in health & consumer products | — |
| 4 | Bioinformax Provider of technological solutions for managing labaratory workflow | — | — | Unfunded | Brad Vose Co-Founder | — | — | — | — |
| 5 | BLESEN Provider of AI-powered fall detection systems | — | — | Unfunded | Ryan Donohue CEO | — | — | — | — |
| 6 | ClearSKY Genomics Provider of a genetics-based diagnosis solution for physicians | — | — | Unfunded | Alan Robertson Founder | — | — | — | — |
| 7 | DMC Developer of device and drug therapeutic for diversified cardiac diseases | — | — | Funding Raised | — | 11 | — | — | 1 job opening · 1 award |
| 8 | DNAQ Provider of DNA testing services for paternity and immigration | — | — | Unfunded | Sandra Stein CEO | — | Cart FunctionalityWordPressMySQL+14 | — | — |
Top 12 Life Sciences companies in Brisbane
#1
Series D · Brisbane, Queensland · founded 2010 · 113 employees$59.3Mraised▾
Developer of a needle-free patch technology for vaccine delivery applications. The company’s technology uses a patch with microprojections applied to the skin. This approach aims to enhance vaccine efficiency and effectiveness. The company’s dry-coating technology reduces the need for vaccine refrigeration during storage and transport. The company targets applications in infectious disease and oncology.
- Aug 2025Conventional Debt$25.2M
- Aug 2025Series D$31.9M
- Dec 2022Series C$23M
- Sep 2022Grant (prize money)$5.5M
#2
Series C · Brisbane, Queensland · founded 2019 · 23 employees$17.4Mraised▾
Radiopharmaceutical company developing targeted alpha therapies for cancer treatment. The company involves a proprietary ²¹²Pb production technology that provides access to alpha isotopes to accelerate the clinical development of drugs for prostate, skin, pancreatic, breast, bladder, colorectal, kidney, lung, and ovary cancer.
- Apr 2025Grant (prize money)$18M
- Feb 2025Series C$112M
- Dec 2023Series B$5M
- Aug 2022Series B$12.4M
#3
Public · Brisbane, Queensland · founded 2017 · 72 employees$2.9Mraised▾
Developer of microbiome-based drug discovery platform. The company uses human data and leading informatics approaches to connect microbial genotype to the human phenotype. It develops a pipeline for inflammatory bowel disease and Immuno-oncology diseases.
- Jun 2025Post IPO$9.3M
- Jun 2023Grant (prize money)—
- Jun 2019Series A$2.9M
#4
Series A · Brisbane, Queensland · founded 2022 · 2 employees$3.1Mraised▾
Developer of robots for arthroscopic surgery. The company's product includes the V01 an arthroscopic robot to make minimally invasive surgery better.
- Jan 2025Series A$3.1M
#5
Public · Brisbane, Queensland · founded 2017$24Mraised▾
EMvision provides portable electromagnetic microwave imaging solution. The company offers a point-of-care, non-invasive, rapid brain scanner for stroke and brain injury diagnosis and monitoring. Their system provides three-dimensional images of biological tissue with microwave tomography.
- Feb 2024Post IPO$10M
- Oct 2022Grant (prize money)$5M
- Jul 2020Post IPO$9M
#6
Series C · Brisbane, Queensland · founded 2000 · 58 employees$98.1Mraised▾
QBiotics, a subsidiary of Ecobiotics is developing small molecules discovered from the natural product (plant extract of Blushwood) for the human & veterinary application. Their lead molecule, EBC-46 (tigilanol tiglate), a phorbol ester is being targeted for the treatment of solid tumor cancers (proof of concept clinical trials are completed). Its mechanism of action is the protein kinase C (PKC) activator. Another molecule, EBC-1013 (WH-1) is being developed for chronic wound treatment.
- Jun 2021Series C$64.4M
- Feb 2020Series B$11.6M
- 2016Series B$22.1M
#7
Series A · Brisbane, Queensland · founded 2005 · 59 employees$7.5Mraised▾
Developer of magnetic resonance imaging devices for the diagnosis of multiple diseases. The company has developed multiple MRI devices by using proprietary technology such as superconducting magnets that help to deliver a more economical MRI system and can be used by clinicians, gradient coils, and radiofrequency coils that can be used in transcranial magnetic stimulation (TMS) and functional MRI studies.
- Dec 2022Series A$7.5M
#8
Series A · Brisbane, Queensland · founded 2018 · 35 employees$5Mraised▾
Developer of wearable sensor technology for real-time personal health monitoring. The company focuses on creating microwearable sensors that capture data from the body's bio-signals. These sensors allow for the detection and treatment of health issues. The initial product is a hydration microwearable sensor designed for continuous monitoring. The technology aims to improve physical and mental performance through advanced machine learning.
- Nov 2022Series A$5M
#9
Funding Raised · Brisbane, Queensland · founded 2023$1.5Mraised▾
Developer of CAR T cell therapies for the treatment of cancer. The company has a proprietary 'Cyt-ATTAC' platform that leverages the unique properties of allogeneic CMV-specific T cells to develop multiple CAR T therapies with dual-targeting capabilities. The company's pipeline includes CYT-101 for treating Glioblastoma Multiforme (GBM) and CYT-AT1 is a dual-targeting cell therapy for treating EphA3-expressing solid tumors.
- May 2023Grant (prize money)$1.5M
#10
Series A · Brisbane, Queensland · founded 2019 · 5 employees$13.7Mraised▾
Kira Biotech is a developer of immunomodulatory compounds for the treatment of immune system disorders. The lead compound is KB31 which is a selective immune-cell depleting monoclonal antibody that is used to target activated immune cells and causes induction of immune tolerance to restore homeostasis.
- Oct 2019Series A$13.7M
#11
Public · Brisbane, Queensland · founded 2011 · 35 employees$10.7Mraised▾
Oventus Medical is involved in developing medical devices for sleep disorders. They have developed O2Vent, a wearable device which is used for treating sleep apnea.
- Dec 2017Post IPO$5.7M
- Jun 2017Post IPO$5M
#12
Series A · Brisbane, Queensland · founded 2010 · 135 employees$5Mraised▾
Ellume has is a developer of a diagnostic device that uses quantum dot fluorescent nanoparticles as biological detectors. It provides real-time patient testing with features such as encrypted patient data and images, connectivity to access user information, and claims to provides results in approximately seven minutes. The company has developed tests for Influenza A+B, Respiratory Syncytial Virus, Group A Streptococcus, and aims to create tests for more respiratory viruses and bacterial infections.
- Feb 2021Grant (prize money)$230M
- Jun 2019Series A$5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Australia
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 861 Australia-affiliated papers.
- University College London67
- The University of Queensland63
- The University of Melbourne59
- Agriculture and Food54
- La Trobe University35
- Mutant2→11
- Genome1→7
- Immune system1→5
- Antibody1→4
- Mitochondrion2→4
- Gene5→17
- Immune system2→13
- Antibody1→10
- Messenger RNA1→10
- Mutant1→9
- Agriculture5→19
- Sustainability3→8
- Emerging technologies1→4
- Resistance (ecology)3→6
- Bacteria2→5
Where biotechnology is researched across Australia
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.